University of Florida Research Foundation, Incorporated

The University of North Carolina at Chapel Hill

Mario Mietzsch

Mavis Agbandje-McKenna

Robert McKenna

Aravind Asokan

James K Smith

Patrick Havlik

The present disclosure provides AAV capsid proteins comprising a modification in the amino acid sequence and virus vectors comprising the modified AAV capsid protein. The disclosure also provides methods of administering the virus vectors and virus capsids of the disclosure to a cell or to a subject in vivo. This disclosure also relates to recombinant adeno associated virus (rAAV) capsid proteins comprising one or more amino acid substitutions in the 5-fold region of the rAAV capsid that result in decreased reactivity to neutralizing antibodies, and their use as gene delivery vehicles.

Methods and compositions for antibody-evading virus vectors

Provided herein are compositions and methods for packaging a recombinant adeno-associated virus (rAAV) particle comprising using inverted terminal repeats (ITRs) and rep genes of different serotypes and/or using chimeric rep genes.

AAV chimeras

This disclosure relates to variant AAVrh 10 particles engineered to escape host neutralizing antibodies but retain or improve transduction efficiency, and their use as gene delivery vehicles.

AAVrh.10 variants with host antibody escape capabilities and altered tissue targeting properties

Provided herein are compositions and methods for packaging a recombinant adeno-associated vims (rAAV) particle comprising using inverted terminal repeats (ITRs) and rep genes of different serotypes and/or using chimeric rep genes.

This disclosure relates to variant AAVrh.10 particles engineered to escape host neutralizing antibodies but retain or improve transduction efficiency, and their use as gene delivery vehicles.

Growing community of inventors

Gainesville, FL, United States of America

Mario Mietzsch